Grace Therapeutics, Inc.
GRCE · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | 0.02 | -0.00 | 0.02 |
| FCF Yield | -54.08% | -55.20% | -71.18% | -93.25% |
| EV / EBITDA | -0.33 | 0.04 | 0.28 | 0.75 |
| Quality | ||||
| ROIC | -17.84% | -13.88% | -56.18% | -11.66% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.56 | 0.96 | 0.38 | 1.76 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | – |
| Free Cash Flow Growth | -20.63% | 22.44% | 7.57% | -19.78% |
| Safety | ||||
| Net Debt / EBITDA | 1.33 | 1.57 | 1.51 | 1.96 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -33,414.09 | 0.00 | 0.00 |